Workflow
金石亚药2024年净利润大降27% “快克”系列收入下滑

Financial Performance - In 2024, the company achieved operating revenue of 1.102 billion yuan, a year-on-year decrease of 8.84% [5] - The net profit attributable to shareholders was 91.76 million yuan, down 27.29% year-on-year [5] - The basic earnings per share were 0.23 yuan per share [5] Key Financial Ratios - The net cash inflow from operating activities was 158 million yuan, an increase of 4.6% year-on-year [4] - The weighted average return on equity was 3.75%, a decrease of 1.65 percentage points year-on-year [4] - The gross profit margin was 57.44%, down 6.44% year-on-year [4] - The asset-liability ratio stood at 19.16%, and the net profit margin was 8.03% [4] Business Segment Performance - The core product "Kuaike" series in the cold medicine segment accounted for 55.49% of revenue but saw a year-on-year decline of 17.16% due to shrinking retail demand and competition from foreign products [4] - Revenue from health food and traditional Chinese medicine slices was 39.09 million yuan, down 7.98% year-on-year, with the new product "Jinxing Glucosamine Soft Capsule" not yet achieving scale [4] - Revenue from complete production lines was 147 million yuan, marking a significant year-on-year increase of 89.95% [4] Research and Development - In 2024, the company's R&D investment was 49.99 million yuan, accounting for 4.54% of revenue [6] - The consistency evaluation for Diclofenac Sodium Sustained-Release Tablets has entered the application stage, and the antiviral drug Oseltamivir Phosphate Capsules have been approved for market [6] - The company plans to accelerate the promotion of "Jinxing Glucosamine Soft Capsule" through e-commerce channels [6] Dividend Distribution - The company plans to distribute a cash dividend of 0.69 yuan per 10 shares (including tax) in 2024 [7] International Expansion - The mechanical segment is providing customized magnetron sputtering vacuum coating equipment to global clients, with a factory planned in Mexico to enhance hydrogen pipeline technology output capabilities [6]